0
0
0
PRICED Act
12/30/2022, 12:04 AM
Summary of Bill HR 7828
The PRICED Act, also known as Bill 117 hr 7828, is a piece of legislation currently being considered by the US Congress. The main goal of this bill is to address the issue of prescription drug pricing in the United States.
The PRICED Act aims to increase transparency in the pharmaceutical industry by requiring drug manufacturers to disclose the costs associated with producing and marketing their medications. This information would then be made available to the public, allowing consumers to better understand why certain drugs are priced the way they are.
Additionally, the bill seeks to promote competition in the market by allowing for the importation of cheaper prescription drugs from other countries. This would give consumers more options when it comes to purchasing their medications and could potentially drive down prices. Furthermore, the PRICED Act includes provisions to prevent drug manufacturers from engaging in anti-competitive practices, such as pay-for-delay agreements that delay the entry of generic drugs into the market. This would help to ensure that consumers have access to affordable medications. Overall, the PRICED Act is aimed at addressing the issue of high prescription drug prices in the United States by increasing transparency, promoting competition, and preventing anti-competitive practices in the pharmaceutical industry.
The PRICED Act aims to increase transparency in the pharmaceutical industry by requiring drug manufacturers to disclose the costs associated with producing and marketing their medications. This information would then be made available to the public, allowing consumers to better understand why certain drugs are priced the way they are.
Additionally, the bill seeks to promote competition in the market by allowing for the importation of cheaper prescription drugs from other countries. This would give consumers more options when it comes to purchasing their medications and could potentially drive down prices. Furthermore, the PRICED Act includes provisions to prevent drug manufacturers from engaging in anti-competitive practices, such as pay-for-delay agreements that delay the entry of generic drugs into the market. This would help to ensure that consumers have access to affordable medications. Overall, the PRICED Act is aimed at addressing the issue of high prescription drug prices in the United States by increasing transparency, promoting competition, and preventing anti-competitive practices in the pharmaceutical industry.
Congressional Summary of HR 7828
Price Relief, Innovation, and Competition for Essential Drugs Act or the PRICED Act
This bill allows biosimilars to be marketed five years after the reference brand-name biological product is licensed. Currently, brand-name biological products are provided a 12-year marketing-exclusivity period.
This shortened marketing-exclusivity period applies only to biological products licensed by the Food and Drug Administration after enactment of this bill.
Read the Full Bill
Current Status of Bill HR 7828
Bill HR 7828 is currently in the status of Bill Introduced since May 18, 2022. Bill HR 7828 was introduced during Congress 117 and was introduced to the House on May 18, 2022. Bill HR 7828's most recent activity was Referred to the House Committee on Energy and Commerce. as of May 18, 2022
Bipartisan Support of Bill HR 7828
Total Number of Sponsors
1Democrat Sponsors
1Republican Sponsors
0Unaffiliated Sponsors
0Total Number of Cosponsors
20Democrat Cosponsors
18Republican Cosponsors
2Unaffiliated Cosponsors
0Policy Area and Potential Impact of Bill HR 7828
Primary Policy Focus
HealthAlternate Title(s) of Bill HR 7828
PRICED Act
PRICED Act
Price Relief, Innovation, and Competition for Essential Drugs Act
To amend the Public Health Service Act to shorten the exclusivity period for brand name biological products from 12 to 5 years.
Comments
Sponsors and Cosponsors of HR 7828
Latest Bills
PROTECT Our Kids Act
Bill HR 1069December 5, 2025
Combating the Lies of Authoritarians in School Systems Act
Bill HR 1005December 5, 2025
Transparency in Reporting of Adversarial Contributions to Education Act
Bill HR 1049December 5, 2025
Made in America Manufacturing Finance Act
Bill HR 3174December 5, 2025
Small Business Regulatory Reduction Act of 2025
Bill HR 2965December 5, 2025
DUMP Red Tape Act
Bill HR 4305December 5, 2025
Improving Access to Workers’ Compensation for Injured Federal Workers Act of 2025
Bill HR 3170December 5, 2025
Make the District of Columbia Safe and Beautiful Act
Bill HR 5103December 5, 2025
SPEED Act
Bill HR 4776December 5, 2025
National Park System Long-Term Lease Investment Act
Bill HR 4931December 5, 2025
Fair Care Act of 2022
Bill HR 8588March 8, 2023




